GlassScriptPhysician profile
Logan C Gibson
NPI 1083009468
$1,970.33
in general payments reported to CMS, 2019-2025
14 companies · $654 in 2025
The $654 reported for 2025 was more than what 77% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.68 · 2022: $180 · 2023: $488 · 2024: $558 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666 · Consulting Fee: $19.00 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.41 |
| Consulting Fee | $19.00 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $585.53 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $460.36 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $199.70 | 2021-2025 | Eohilia, Gattex |
| Abbvie INC. | $176.11 | 2021-2025 | |
| Qol Medical, LLC | $151.36 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $128.11 | 2024 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $49.72 | 2023-2025 | Bylvay |
| Mirum Pharmaceuticals, INC. | $46.10 | 2023-2025 | Cholbam, Livmarli |
| Sandoz INC. | $35.75 | 2024 | Hyrimoz |
| Echosens North America, INC. | $34.18 | 2023-2024 | Fibroscan |
| Alexion Pharmaceuticals, INC. | $30.48 | 2025 | Ultomiris |
| Ironwood Pharmaceuticals, INC | $29.15 | 2024 | |
| Albireo Pharma, INC. | $28.88 | 2023 | Bylvay |
| Aimmune Therapeutics, INC. | $14.90 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.